Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase II Adaptive Modification of Neoadjuvant Therapy Based on Clinical Response in Patients With Localized Pancreatic Cancer

Summary

The purpose of this phase II study is to evaluate the efficacy of adaptive modification of neoadjuvant therapy in patients with resectable and borderline resectable pancreas cancer.

General Information

NCT#: NCT03322995
Study ID: PRO00030656
Trial Phase: Phase II

Trial Sponsor: Medical College of Wisconsin
Therapies Used in This Trial: Fluorouracil, Gemcitabine, Oxaliplatin, Irinotecan, Leucovorin, FOLFIRINOX, Physician's discretion on standard of care

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search